A new study has reportedly suggested that the administration of Human Papillomavirus (HPV) vaccine could greatly benefit women who have pre-cancerous cells on their cervix by reducing the risk of relapse.
For the uninitiated, the HPV vaccine is routinely administered to children, both boys and girls, between ages 12 and 13 and helps prevent cancers caused by the human papillomavirus, such as cervical cancer, head or neck cancer, and anal cancer.
The vaccine that came into being in 2008, is not routinely offered to those who then exceeded 13 years of age. This was because several studies then found that after someone is infected with HPV, the vaccine is not much effective. It reacts better at a younger rather than older age.
However, according to a recent study, women who have been identified to have high-grade pre-cancerous cells on their cervix and have a life-long risk of acquiring cervical cancer, might be able to avoid that with the HPV vaccine.
It has been suggested that the jab might help prevent the lesions from returning and may even protect against other HPV-caused cancers.
Academics examined 18 previously done investigations on the topic for the study published in The BMJ.
The study revealed a 75% reduction in the reappearance of high-grade preinvasive disease among people who received the vaccine and were also surgically treated for cervical lesions than those who did not receive the jab.
The results showed even stronger findings in women who were identified to be carrying the HPV strain mostly correlated to cervical cancer.
However, study’s author stressed the fact that further work is required to confirm the findings.
They wrote that during local excision, which refers to examining the lesions or tumor before performing any surgery, use of the HPV vaccine may reduce the risk of high-grade preinvasive disease reappearing.
But to confirm the findings, they wrote that large-scale and aptly-powered randomized controlled trials need to be conducted to demonstrate the effectiveness of the vaccine while surgically treating the cervical preinvasive disease.